NCT03369301View on ClinicalTrials.gov

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

November 22, 2019

Study Completion Date

November 22, 2019

Conditions
Secondary Immune Deficiency
Interventions
DRUG

Gammanorm

Gammanorm given per standard of care

DRUG

Other Subcutaneous Immunoglobulins

Other Subcutaneous Immunoglobulins given per standard of care

Trial Locations (6)

17000

CH la Rochelle - Hôpital Saint Louis, La Rochelle

33604

CHU Bordeaux Centre François Magendie Hopital Haut -Lévêque, Pessac

35400

CH Saint Malo, St-Malo

45100

CH Orléans, Orléans

71100

CH William Morey Chalon-sur-Saône, Chalon-sur-Saône

85000

CHD Vendée, La Roche-sur-Yon

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT03369301 - The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency | Biotech Hunter | Biotech Hunter